The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 No. 775

PART 15 U.K. Amendment of Part 14 (advertising)

Amendment of Schedule 30 (particulars for advertisements to persons qualified to prescribe or supply) U.K.

[F1 216.   In Schedule 30—

(a) in paragraphs 1, 2 and 6, for “marketing authorisation,” substitute “UK marketing authorisation, EU marketing authorisation”;

(b) after paragraph 2 insert—

“2A.   In relation to an advertisement in Great Britain (other than an advertisement falling within the exception in regulation 296) where the medicinal product concerned is authorised under a UKMA(GB), a statement that the product concerned is authorised under a UKMA(GB).”.]

Textual Amendments

F1 Reg. 216 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 175

Commencement Information

I1 Reg. 216 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1